Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety...

Full description

Saved in:
Bibliographic Details
Published in:Cytotherapy (Oxford, England) England), 2022-07, Vol.24 (7), p.742-749
Main Authors: Stewart, Mark D., McCall, Bruce, Pasquini, Marcelo, Yang, Allen S., Britten, Carolyn D., Chuk, Meredith, De Claro, R Angelo, George, Bindu, Gormley, Nicole, Horowitz, Mary M., Kowack, Eric, McCoy, Candice, Morrow, Phuong Khanh, Okoye, Emmanuel, Ricafort, Rosanna, Rossi, John, Sharon, Elad, Theoret, Marc, Vegni, Ferdinando, Yu, Tai, Allen, Jeff
Format: Article
Language:English
Subjects:
Cytokine Release Syndrome (CRS)
Drug development
Immunotherapies
T cell receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety of adverse events that may accompany CRS and for recognizing that presentations of CRS may differ among various immunotherapies (e.g., monoclonal antibodies, CAR T cell therapies and T cell engagers, which can include bispecific antibodies and other constructs). The goals of this paper are to ensure accurate and consistent identification of CRS in patients receiving immunotherapies in clinical studies to aid in reporting; enable more precise evaluation of the therapeutic risk–benefit profile and cross-study analyses; support evidence-based monitoring and management of important toxicities related to cancer immunotherapies; and improve patient care and outcomes. These efforts will become more important as the number and variety of molecular targets for immunotherapies broaden and as therapies with novel mechanisms continue to be developed.
ISSN:1465-3249
1477-2566
1477-2566
DOI:10.1016/j.jcyt.2022.01.004